Inflammation in Atherosclerosis-No Longer a Theory

Area of Science:

• Cardiovascular Medicine
• Immunology
• Pharmacology

Background:

• Inflammation is a known contributor to atherosclerosis and its complications.
• Biomarkers of inflammation, such as C-reactive protein, correlate with cardiovascular events.
• Inflammatory status can guide statin therapy for primary prevention in specific patient groups.

Purpose of the Study:

• To review the evidence for anti-inflammatory interventions in atherosclerosis.
• To highlight the clinical translation of targeting inflammation for cardiovascular event reduction.
• To discuss future directions in anti-inflammatory therapy for atherosclerosis.

Main Methods:

• Review of preclinical investigations and human clinical trials.
• Analysis of studies involving interleukin-1 beta neutralization.
• Evaluation of colchicine's efficacy in coronary artery disease patients.

Main Results:

• A large trial demonstrated that neutralizing interleukin-1 beta reduced major adverse cardiac events in post-myocardial infarction patients.
• Subsequent studies confirmed colchicine's ability to prevent recurrent events in coronary artery disease.
• These findings establish the clinical efficacy of anti-inflammatory strategies in atherosclerosis.

Conclusions:

• Anti-inflammatory interventions have transitioned from theoretical concepts to practical clinical applications in atherosclerosis management.
• Further research is needed to optimize patient selection and minimize potential side effects of these therapies.
• Targeting inflammation represents a significant advancement in reducing residual cardiovascular risk.